01 / 05
Cancer and Heart Disease Death Rates Have Declined in 150 Countries Since 2010

Nature | Noncommunicable Disease

Cancer and Heart Disease Death Rates Have Declined in 150 Countries Since 2010

“The chance of dying from chronic illnesses such as heart disease, cancer and diabetes declined in four out of five countries between 2010 and 2019, finds a study of 185 countries published in The Lancet today [9/10/25].

Non-communicable diseases (NCDs) are the leading cause of death globally. The United Nations has set the goal of reducing deaths from these diseases by one-third by 2030.

The latest study is the first to investigate the change in NCD mortality across countries. It finds that, from 2010 to 2019, the probability of dying from an NCD before the age of 80 fell in 152 countries for women and in 147 countries for men.”

From Nature.

Nature | Noncommunicable Disease

Gene Therapy Trial Cuts Seizures in Three Epilepsy Patients

“Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90%, after gene-laden viruses were infused directly into their brains as part of an early-stage clinical trial.

In each participant, the gene therapy was precisely targeted to a small patch of brain tissue that was the source of their seizures. The viruses carried a gene that makes neurons sensitive to a specific drug, which works like a dimmer switch for the therapy. By combining gene therapy with a drug — an approach known as chemogenetics — researchers can adjust a treatment’s potency, which is not possible with other types of gene therapy. The trial participants did not experience serious side effects.”

From Nature.

Medical Xpress | Noncommunicable Disease

CAR T May Improve Mobility in Stiff Person Syndrome

“New research led by the University of Colorado Anschutz is offering hope to people living with stiff person syndrome (SPS), showing that a CAR T-cell therapy may help change the course of the disease….

SPS is a rare, progressive autoimmune neurological disease that causes debilitating muscle stiffness, painful spasms and difficulty walking. An estimated 80% of patients eventually require walking assistance or a wheelchair, and many face a risk of permanent disability…

One year after receiving a single treatment of the experimental therapy, patients with SPS demonstrated significant improvements in mobility, completing a 25-foot walking test in nearly half the time it took before treatment. Also, two-thirds of patients who initially needed walking aids were able to complete a walking test without assistance. Beyond walking improvements, patients also experienced lasting reductions in muscle stiffness, sensitivity to stimuli and overall disability.”

From Medical Xpress.

The ASCO Post | Noncommunicable Disease

mRNA Combo Cuts High-Risk Melanoma Relapse

“Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA1). The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.”

From The ASCO Post.

Nature | Noncommunicable Disease

Prime Editing Used in a Patient for First Time

“A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.

The milestone treatment is part of a clinical trial of prime editing, a technique that can alter DNA with more precision than standard CRISPR–Cas9 methods can. In this case, prime editing was used to treat a condition called Wilson’s disease by rewriting DNA in liver cells, to erase a mutation that prevents them from eliminating excess copper.

Prime Medicine, a biotechnology company in Cambridge, Massachusetts, announced that it had treated the first person in its trial earlier this month. It expects to announce the first results from the study next year.”

From Nature.